How to use the aortic valve calcium score to improve the results of transcatheter aortic valve implantation with a self-expanding prosthesis.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
May 2022
Historique:
received: 09 06 2021
revised: 27 02 2022
accepted: 01 03 2022
pubmed: 9 5 2022
medline: 9 6 2022
entrez: 8 5 2022
Statut: ppublish

Résumé

In recent years, transcatheter aortic valve implantation (TAVI) without predilation (direct TAVI) has become the preferred method for implanting TAVI prostheses. Appropriate patient selection is important to avoid suboptimal outcomes and associated complications. To evaluate whether aortic valve calcification measured with computed tomography predicts suboptimal results from direct TAVI with a self-expanding prosthesis. Single-centre retrospective analysis of patients who received a CoreValve™ prosthesis (Medtronic, Minneapolis, MN, USA) in a direct TAVI procedure between January 2018 and March 2019. Aortic valve calcification assessment (aortic valve calcium score, calcium volume and calcium mass) was calculated from the computed tomography scan before TAVI. Procedural characteristics, need for postdilation and complications were analysed. Of 168 included patients, 18 were postdilated. Aortic valve calcium score (4259 vs. 2578; P<0.001), calcium volume (1184 vs. 647mm A high aortic valvular calcium score, assessed by computed tomography scan, is an independent predictor of suboptimal prosthesis implantation outcomes in direct TAVI.

Sections du résumé

BACKGROUND BACKGROUND
In recent years, transcatheter aortic valve implantation (TAVI) without predilation (direct TAVI) has become the preferred method for implanting TAVI prostheses. Appropriate patient selection is important to avoid suboptimal outcomes and associated complications.
AIM OBJECTIVE
To evaluate whether aortic valve calcification measured with computed tomography predicts suboptimal results from direct TAVI with a self-expanding prosthesis.
METHODS METHODS
Single-centre retrospective analysis of patients who received a CoreValve™ prosthesis (Medtronic, Minneapolis, MN, USA) in a direct TAVI procedure between January 2018 and March 2019. Aortic valve calcification assessment (aortic valve calcium score, calcium volume and calcium mass) was calculated from the computed tomography scan before TAVI. Procedural characteristics, need for postdilation and complications were analysed.
RESULTS RESULTS
Of 168 included patients, 18 were postdilated. Aortic valve calcium score (4259 vs. 2578; P<0.001), calcium volume (1184 vs. 647mm
CONCLUSION CONCLUSIONS
A high aortic valvular calcium score, assessed by computed tomography scan, is an independent predictor of suboptimal prosthesis implantation outcomes in direct TAVI.

Identifiants

pubmed: 35527213
pii: S1875-2136(22)00047-X
doi: 10.1016/j.acvd.2022.03.001
pii:
doi:

Substances chimiques

Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

305-314

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

Guillaume Clerfond (G)

Service de Cardiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000 Clermont-Ferrand, France; INI-CRCT F-CRIN, 54500 Vandœuvre-lès-Nancy, France. Electronic address: gclerfond@chu-clermontferrand.fr.

Nicolas Combaret (N)

Service de Cardiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000 Clermont-Ferrand, France.

Jean Pascal Salazard (JP)

Service de Cardiologie, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.

Andrea Innorta (A)

Service de Chirurgie Cardiaque, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.

Bruno Pereira (B)

Unité de Biostatistique, Direction de la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.

Romain Eschalier (R)

Service de Cardiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000 Clermont-Ferrand, France; INI-CRCT F-CRIN, 54500 Vandœuvre-lès-Nancy, France.

Pascal Motreff (P)

Service de Cardiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000 Clermont-Ferrand, France.

Pascal Chabrot (P)

Service de Radiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000 Clermont-Ferrand, France.

Géraud Souteyrand (G)

Service de Cardiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000 Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH